Salvage Surgery for Advanced Lung Adenocarcinoma after EGFR Tyrosine Kinase Inhibitor Treatment

Mong-Wei Lin,Sung-Liang Yu,Yin-Chen Hsu,Yan-Ming Chen,Yi-Hsuan Lee,Yi-Jing Hsiao,Jing-Wei Lin,Te-Jen Su,Chi-Fu Jeffrey Yang,Xu-Heng Chiang,Hsao-Hsun Hsu,Jin-Shing Chen,Min-Shu Hsieh

DOI: https://doi.org/10.1016/j.athoracsur.2023.01.027

2023-02-04

Abstract:BACKGROUND No published studies have evaluated the detailed pathological and genetic features of lung adenocarcinoma after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and salvage surgery. We aimed to evaluate the pathological and genetic changes of tumors in patients with advanced lung adenocarcinoma treated with EGFR TKI therapy and salvage surgery. METHODS This study retrospectively collected data from 29 advanced lung adenocarcinoma patients who underwent EGFR TKI therapy followed by salvage surgery between January 2010 and December 2018. All patients had partial response or stable disease without evidence of progressive disease. Next generation sequencing was used to determine whether acquired resistant mutations in morphologically treatment-sensitive and morphologically treatment-resistant regions of tumor existed. RESULTS There were 3, 22, and 4 patients of clinical stage IIIB, IVA, and IVB, respectively. After a mean TKI treatment duration of 134 days, 27 patients had partial response and 2 had stable disease. 30% of patients were downstaging before salvage surgery. All patients had residual viable tumor cells in their tumor bed; 5 patients (17.2%) had major pathological response. Acquired T790M mutations (n=4), histologic transformations (n=2), and acquired T790M mutation with histologic transformation (n=1) were identified in the morphologically treatment-resistant regions of tumors. The 3-year overall survival was 75.9%. CONCLUSIONS The presence of morphologically treatment-resistant tumor regions with acquired T790M mutations and histologic transformations demonstrate the existence of resistant subclones in TKI-treated tumors before disease progression. Salvage surgery performed in selected patients prior to disease progression may improve survival by removing TKI-resistant subclones.

surgery,cardiac & cardiovascular systems,respiratory system